Multiple Myeloma
Conditions
Keywords
Multiple Myeloma, Fludarabine, Fludara, Fludarabine Phosphate, Melphalan, Alkeran, Stem Cell Infusion, Stem Cell Transfusion, SCT, Allogeneic Peripheral Blood Stem Cell Transfusion, APBSCT, Bone Marrow Transplantation, BMT, Rituxan, Rituximab, FM140, FM100
Brief summary
The goal of this clinical research study is to learn if there is a difference in transplant outcomes between two different doses of melphalan given in combination with fludarabine followed by transfusion of a related or unrelated volunteer donor's peripheral blood or bone marrow progenitor cells (allogeneic stem cell transplant) in patients with multiple myeloma. This study will also look at whether treatment with a antibody called rituximab against a specific type of lymphocyte (B cell) will reduce the risks of developing graft versus host disease after transplant. The safety of these treatments will also be compared.
Detailed description
Fludarabine is a chemotherapy drug that is used in various diseases. Melphalan is a chemotherapy drug that has been widely used in the treatment of multiple myeloma for many years. Before beginning therapy, patients will have a complete work-up. This includes a bone marrow aspiration and biopsy, bone survey, blood tests, and tests to check the heart and lung function. All patients will receive tacrolimus and methotrexate to prevent graft-versus-host disease. Patients in this study will be randomly picked (as in the toss of a coin) to be in one of two treatment groups. There is an equal chance that a patient will be in either group. Patients in the first group will receive fludarabine through the vein every day for four days. On the fourth day, patients will receive a dose of melphalan through the vein over 20 minutes. On the following day, patients will receive the donor cells as an infusion through their catheter. Patients in the second group will receive fludarabine through the vein every day for four days. Patients in this group will receive a lower dose of melphalan through the vein over 20 minutes. After the last dose of fludarabine, patients will receive the donor cells as an infusion through their catheter the next day. If you have an unrelated or a mismatched donor, you will receive the drug ATG (Thymoglobulin) by vein over 6 hours on Days -3, -2, and -1 (the 3 days before the transplant), to prevent graft versus host disease (GVHD) and to help engraftment. Patients in both group will be receiving the monoclonal antibody called rituximab weekly starting on the fifth day before the stem cell transplant for a total of 4 doses. Patients will remain in the hospital for about 4-6 weeks and in Houston Medical Center area at least 100 days after transplantation. Patients whose disease gets worse will be taken off study. These patients will continue to be followed for survival. This is an investigational study. All of the drugs used in this study are commercially available. The FDA has approved melphalan for the treatment of myeloma. Fludarabine is not approved for the treatment of myeloma but has been used for years as a way to prepare patients for transplant. About 30 to 60 patients will take part in this study. About 45 patients will be enrolled at M. D. Anderson.
Interventions
DRUGMelphalan
Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.
DRUGFludarabine
30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
PROCEDUREStem Cell Infusion
Stem Cell Infusion on Day 0.
DRUGRituximab
375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with Multiple Myeloma in any of the following disease categories: a) Primary Refractory considered poor candidate for autologous transplant, b) Remission Consolidation in patients with Chromosome 13 abnormalities or plasma cell leukemia, c) All relapsing patients. 2. Age up to 70 years. 3. Related or unrelated donor who is HLA-compatible in at least 9/10 alleles (A,B, C, DRB1 and DQ) by molecular techniques. 4. Zubrod Performance Score (PS)\<2. 5. Life expectancy is not severely limited by concomitant illness. Left ventricular ejection fraction \>40%. No uncontrolled arrhythmias or symptomatic cardiac disease. Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) \>40%. 6. Patient and donor or guardian willing and able to sign informed consent.
Exclusion criteria
1\) Patients with active central nervous system (CNS) disease are ineligible for this study as documented by clinical symptoms and/or testing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants With Successful Engraftment at Day 100 | Day 100 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acute Grade II-IV Graft Versus Host Disease (GVHD) | GVHD grading weekly during first 100 days; Annual examinations for nine year study period | Effects of Rituximab as measured by percentage of participants with Acute and Chronic Graft Versus Host Disease (GVHD) incidences after allogeneic transplantation. GVHD occurring anytime after day 90 post transplant was considered chronic GVHD; otherwise it was considered acute GVHD. Acute GVHD status defined as GVHD with maximum grade ≥2. Clinical grading of Acute GVHD (Thomas et al., New England Journal of Medicine (NEJM), 229:895, 1975): Grade 1 to 4. |
Countries
United States
Participant flow
Recruitment details
Recruitment Period: January 18, 2002 to July 27, 2011. All recruitment done in a medical clinical setting.
Pre-assignment details
Of the 52 participants enrolled, two were not included due to one patient experiencing pulmonary complication and another not completing the study follow up requirement.
Participants by arm
| Arm | Count |
|---|---|
| Fludarabine + Melphalan + Stem Cell Infusion Fludarabine 30 mg/m\^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).
Melphalan 140 mg/m\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\^2 IV infused starting on day -5. | 27 |
| Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion Fludarabine 30 mg/m\^2 intravenous daily over 30 minutes for 4 Days (Beginning Day -4).
Lower-Dose Melphalan 100 mg/m\^2 intravenous over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\^2 intravenous infused starting on day -5. | 23 |
| Total | 50 |
Baseline characteristics
| Characteristic | Fludarabine + Melphalan + Stem Cell Infusion | Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion | Total |
|---|---|---|---|
| Age, Continuous | 52 years | 53 years | 53 years |
| Region of Enrollment United States | 27 participants | 23 participants | 50 participants |
| Sex: Female, Male Female | 8 Participants | 12 Participants | 20 Participants |
| Sex: Female, Male Male | 19 Participants | 11 Participants | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 8 / 27 | 10 / 23 |
| serious Total, serious adverse events | 23 / 27 | 16 / 23 |
Outcome results
Primary
Number of Participants With Successful Engraftment at Day 100
Time frame: Day 100
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fludarabine + Melphalan + Stem Cell Infusion | Number of Participants With Successful Engraftment at Day 100 | 27 participants |
| Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion | Number of Participants With Successful Engraftment at Day 100 | 23 participants |
Secondary
Acute Grade II-IV Graft Versus Host Disease (GVHD)
Effects of Rituximab as measured by percentage of participants with Acute and Chronic Graft Versus Host Disease (GVHD) incidences after allogeneic transplantation. GVHD occurring anytime after day 90 post transplant was considered chronic GVHD; otherwise it was considered acute GVHD. Acute GVHD status defined as GVHD with maximum grade ≥2. Clinical grading of Acute GVHD (Thomas et al., New England Journal of Medicine (NEJM), 229:895, 1975): Grade 1 to 4.
Time frame: GVHD grading weekly during first 100 days; Annual examinations for nine year study period
Population: For the acute GVHD analysis, only 48 patients' data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fludarabine + Melphalan + Stem Cell Infusion | Acute Grade II-IV Graft Versus Host Disease (GVHD) | Acute GVHD | 22 percentage of participants |
| Fludarabine + Melphalan + Stem Cell Infusion | Acute Grade II-IV Graft Versus Host Disease (GVHD) | Chronic GVHD | 29 percentage of participants |
| Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion | Acute Grade II-IV Graft Versus Host Disease (GVHD) | Acute GVHD | 21 percentage of participants |
| Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion | Acute Grade II-IV Graft Versus Host Disease (GVHD) | Chronic GVHD | 48 percentage of participants |